Development and analytical validation of real-time PCR for the detection of Streptococcus agalactiae in pregnant women

Daniel F. Escobar, Diego A. Diaz-Dinamarca, Carlos F. Hernández, Daniel A. Soto, Ricardo A. Manzo, Pedro I. Alarcón, Camila H. Pinto, Diego N. Bastias, Carolayn N. Oberg-Bravo, Robert Rojas, Sebastián E. Illanes, Alexis M. Kalergis and Abel E. Vasquez

Abstract

Background: Group B Streptococcus (GBS) is the leading cause of invasive neonatal infection. In this study, we aimed to evaluate the analytical validation of qualitative real-time polymerase chain reaction (qPCR) as a means to detect GBS.

Methods: Genomic DNA (gDNA) was purified from 12 ATCC bacterial strains, two belonging to GBS and the remainder acting as negative controls. Additionally, gDNA was isolated from 21 strains of GBS from various serotypes (Ia, Ib and II-VIII). All gDNA was used to evaluate the analytical validation of the qPCR method employing a specific Taqman probe. Inclusivity, exclusivity, anticipated reportable range, the limit of detection and robustness were evaluated. The methods used are described in international guidelines and other existing reports. The performance of this qPCR method for detecting GBS was compared to other microbiological methods used with vaginal-rectal samples from pregnant women.

Results: Our qPCR method for detecting GBS was analytically validated. It has a limit of detection of 0.7 GE/μL and 100% analytical specificity. It detects all strains of GBS with the same level of performance as microbiological methods.

Conclusion: Data suggest that this qPCR method performs adequately as a means to detect GBS in vaginal-rectal swabs from pregnant women.

Keywords: Group B Streptococcus, qPCR, Surface immunogenic protein, Analytical validation, Bacterial detection
Background

*Streptococcus agalactiae*, also known as Group B *Streptococcus* (GBS), is a leading cause of sepsis and meningitis in newborns and young infants [1–3]. Colonisation in pregnant women is estimated to be 11 to 35%, and socioeconomic factors directly impact the percentage of carriers in the population [4]. Even though screening programs and intrapartum antibiotic prophylaxis has reduced early neonatal onset of disease, this bacteria remains the leading cause of infection in newborns in developing countries [2, 5, 6].

The Centers for Disease Control and Prevention (CDC) recommends that vaginal and rectal swabs be used to inoculate a selective enrichment medium such as Lim broth and subsequently subculture the product on blood agar plates [2]. For better sensitivity or test efficiency, an alternative such as Granada medium could be used. In this case, a color change indicates GBS growth [7]. Unfortunately, this approach has variable sensitivity [8–10] and is associated with long turnaround times (18–72 h). A more rapid test that retains high sensitivity and specificity compared to conventional culture-based methods is real-time polymerase chain reaction (qPCR) [11]. This method will not fail to detect non-hemolytic GBS, as do culture-based methods. Non-hemolytic and non-pigmented GBS are reportedly found in 1 to 4% of pregnant women [12].

It is crucial that sensitive and accurate qPCR strategies be developed so that the efficacy of intrapartum antibiotic prophylaxis can be determined [7]. Also essential is the analytical validation of the method by evaluating parameters such as analytical specificity (inclusivity and exclusivity), analytical sensibility (anticipated reportable range and limit of detection), linearity, efficiency and robustness, when used for detection. Quantitative methodologies require estimates of precision, accuracy and limits of quantification [13]. A validated analytical method confirms that GBS detection will be an accurate, precise and reliable measure of potency.

A surface immunogenic protein (SIP) is reportedly exposed at the surface of intact GBS cells no matter the serotype [14, 15]. Because the *sip* gene is conserved in GBS, qPCR strategies have been used to successfully detect GBS in clinical studies [16–20]. However, an analytically validated qPCR assay for GBS using the target *sip* gene has not yet been reported.

We developed a qPCR method that uses the *sip* gene as its target (Intellectual Property PCT/IB2017/056506), and herein, we report the analytical validation and standardisation of that method using Clinical and Laboratory Standards Institute (CLSI) guidelines MM17-A (Validation and Verification of Multiplex Nucleic Acid Assays) and EP17-A (Protocols for Determination of Limits of Detection and Limits of Quantitation and Evaluation) [21–23]. Based on the work of others, the relevant parameters were identified as: selectivity (inclusivity and exclusivity), anticipated reportable range, the limit of detection (LOD), linearity, efficiency and robustness [24–28].

Methods

Design of oligonucleotides

Oligonucleotides were designed using free online software (Amplifx 1.7.0). They were based on the GBS *sip* gene, which codes for the GBS SIP (GenBank accession no.KX363665.1). After in silico analysis using Blast, the set of oligonucleotides showing the greatest sensitivity and specificity were: forward (SIP-F), GTTCCAGCAGCTAAAGAGGAAG; reverse (SIP-R), CCGGTGCTACTTTAGCTACTGG; and probe (SIP-P), FAM-CACCAAGCTGTTGGCCGTGAAAACCCAGC-BHQ1 (Supplementary Fig. 1). A PCR product of 118 bp was obtained (Supplementary Fig. 2) (Intellectual Property PCT/IB2017/056506).

Collection of clinical samples

Vaginal-rectal swabs were collected from pregnant women at a private health center and sent to the Health Public Institute of Chile ISPCH for GBS detection. All samples (*n* = 103) were collected between the 35th and 37th weeks of pregnancy. The study protocol was approved by the Ethics Committee of Clínica Dávila, and written informed consent was obtained from all study participants, agreeing that this work can be published. Samples were collected and submitted to Stuart transport medium at room temperature at the health center. After 2 hours, samples were cooled to 4°C with ice packs, collected in a tertiary container and sent for analysis.

Collection strains

To perform standardisation and to determine the analytical parameters of the methodology, specific reference strains were obtained from the American Type Culture Collection (ATCC): *Streptococcus agalactiae* ATCC 12403, *Streptococcus agalactiae* ATCC 13813, *Streptococcus pyogenes* ATCC 21547, *Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *Streptococcus pneumoniae* ATCC 49619, *Escherichia coli* ATCC 25922, *Klebsiella pneumoniae* ATCC 700603 and *Klebsiella aerogenes* ATCC 13048. Three non-ATCC strains, confirmed by the ISPCH, were included: *Staphylococcus saprophilicus*, *Proteus* spp. and *Serratia marcescens*. Isolates of axenic cultures of nine serotypes of GBS (*n* = 21) from patients with invasive infections (received from 2013 to 2018 by the Bacteriology Reference Laboratory of the ISPCH for confirmation) were also used.
**Pretreatment of vaginal-rectal swabs**

All vaginal swabs were inoculated in 3 mL selective Todd-Hewitt broth and supplemented with nalidixic acid (15 μg/mL; Sigma-Aldrich, St. Louis, MO, USA) and gentamicin (8 μg/mL; Sigma-Aldrich), then were incubated for 18 to 24 h at 37 °C in an atmosphere of 5% CO₂. This procedure was duplicated; one was analysed using qPCR and the other using a microbiological method (Granada agar, Christie, Atkins and Munch-Peterson [CAMP] test and latex agglutination; Fig. 1).

**DNA extraction from clinical samples**

Bacterial cultures were centrifuged at 10,000 g for 10 min. Then, from each pellet, a portion with a sterile tip was resuspended in 200 μL 5% Chelex-100 (Sigma-Aldrich), 1 μL commercial human DNA (10 ng/μL) and 10 μL lysozyme (5 mg/mL, Biological, Salem, MA, USA). The mixture was incubated at 37 °C for 15 min, then, 10 μL proteinase K (2 mg/mL, Merck) was added. Incubation at 56 °C for 15 min was followed by a one-step inactivation (95 °C for 15 min). Finally, the lysate bacterial culture was centrifuged at 10,000 g for 3 min then stored at −20 °C until qPCR analysis.

**DNA isolation from each strain**

All strains used for the determination of analytical parameters (previously characterised strains, both ATCC and non-ATCC) were cultured in blood agar, and gDNA was then extracted using E.Z.N.A. A manual bacterial DNA kit (OMEGA Bio-Tek, Norcross, GA, USA) was applied following manufacturer instructions. Genetic material was eluted using 100 μL eluent, then samples were screened for GBS using qPCR. The gDNA was quantified using a DS-11 spectrophotometer (Denovix, Wilmington, DE, USA). To determine the number of genomic equivalents, one GBS genome (2.16 Mbp) was obtained from the NCBI Reference Sequence (GenBank accession no. NC_004116.1), and its mass was calculated using: \( \text{bp} \times M \times N_A \), where \( \text{bp} \) is the size of the genome in bp, \( M \) is its molar mass in g/mol and \( N_A \) is Avogadro’s number in mol\(^{-1}\). One genomic equivalent of GBS was found to have a mass of 2.4 fg.

**Real-time PCR procedure**

Assays were performed using 1 μL gDNA template and a Stratagene Mx3000P thermocycler (Agilent Technologies, Santa Clara, CA, USA). To detect GBS, 1 μL of each primer (4 μM stock), 1 μL probe (2 μM stock) and 10 μL Brilliant Multiplex Real-Time PCR Master Mix (Agilent Technologies, Santa Clara, CA, USA) were used. The optimal reaction conditions were found to be 95 °C for 10 min followed by 40 cycles at 95 °C for 15 s, then 60 °C for 1 min. A cycle threshold (\( \text{Ct} \)) value of 35 was used as the cut-off for positive fluorescence detection of the target.

**Analytical specificity**

Analytical specificity was evaluated in terms of selectivity, given the responsiveness of the method to selectively

---

*Fig. 1 Working scheme of the clinical vaginal-rectal swab specimens collected (\( n = 103 \)). *Genetic characterisation data not shown*
identify DNA sources using the *sip* target (GBS DNA) in non-GBS sources. This feature included:

**Inclusivity**
Purified gDNA from *S. agalactiae* ATCC 12403 was prepared at concentrations of 24, 120 and 240 fg/μL (10, 50 and 100 GE/μL) for nine available serotypes (Ia, Ib, II, III, IV, V, VI, VII and VIII). Each was run in duplicate.

**Exclusivity**
Purified DNA from *S pyogenes, S. aureus, E. faecalis, S. pneumoniae, E. coli, K. pneumoniae, K. aerogenes, S. saprophyticus, Proteus spp.* and *S. marcescens* was prepared at concentrations of 1, 10, 100 and 1000 pg/μL for each. Each was run in duplicate.

**Analytical sensitivity**
Analytical sensitivity, the lowest amount of analyte that can be detected with (a stated) probability was evaluated. However, exact values were not the focus. This feature includes:

**Anticipated reportable range**
Serial dilutions of gDNA from *S. agalactiae* ATCC 12403 resulted in final concentrations between 4.8E04 and 0.48 fg/μL (20,000 to 0.2 GE/μL). Each dilution was amplified six-fold in four qPCR assays, providing 24 data points for the standard curve. Assigned (theoretical) versus measured values were converted to log_{10} (GE/μL) and were then plotted for linear regression analysis.

**Limit of detection**
According to the CLSI guidelines, the LOD is the lowest DNA concentration that provides at least 95% detectable results. Four concentrations of purified gDNA were adjusted to 9.6, 19.2, 38.4 and 76.8 fg/μL (32 to 4 GE/μL) and were analysed using qPCR. A blank (pooled negative samples) was also included. A total of 60 points and blanks were obtained over the course of five consecutive days. According to the CLSI protocol, to determine LOD, the limit of blank (LOB), the highest qPCR measures expected in samples devoid of analyte, must be determined.

**Robustness**
To evaluate a test’s robustness, combinations between factors in standardised and alternative conditions were generated. The factors analysed were: master mix, concentration of primers, concentration of probe, upper alignment temperature, lower alignment temperature, equipment and operator. (Table 1).

**Precision**
Three concentrations of purified gDNA from *S. agalactiae* ATCC 12403 were adjusted to 4.8, 9.6 and 240 fg/μL (2, 4 and 100 GE/μL or 0.3, 0.6 and 2 log_{10} GE/μL). Precision was found using CLSI recommendations (the 20x2x2 method, performing 2 daily runs of duplicates on 20 different days). The estimates of within-laboratory precision standard deviation (SR) and repeatability standard deviation (SR) were calculated using: 

\[ S_{WL} = \sqrt{\frac{\sum_{i=1}^{n} (V_{day} + V_{run} + V_{error})}{n_{day} n_{run} n_{rep}}} \]

where \( V_{day}, V_{run} \) and \( V_{error} \) correspond to variance components of the day, run, and error, respectively. The variance component was calculated using MS, the mean of the square: 

\[ V_{error} = MS_{error}; V_{run} = MS_{run} - MS_{error} n_{rep} \]

(number of replicates per run); 

\[ V_{day} = MS_{day} - MS_{run} / n_{rep} \]

(number of runs per day; number of replicates per run). The sum of the squares, provided by the two-way nested analysis of variance, was used to calculate MS, and DF, the degrees of freedom (for each source of variation), was obtained as: 

\[ DF_{day} = n - 1; DF_{run} = (n_{run} - 1) n_{day}; DF = N - n_{day} n_{run} n_{rep} \]

and DF_{total} = N - 1, where \( n_{day} = 20 \) days; \( n_{run} = 2 \) runs per day; \( n_{rep} = 2 \) replicates per run and \( N = 80 \) results per sample.

Two-sided 95% confidence intervals (CIs) were calculated using the standard deviations of the degrees of freedom associated with repeatability (df_{error}) and the degrees of freedom associated with the laboratory (df_{WL}), where \( \alpha_{day} = 0.25, \alpha_{run} = 0.25 \) and \( \alpha_{error} = 0.5 \), using the following formulas, respectively: 

\[ df_{R} = N - n_{day} n_{run} \]

\[ df_{WL} = (\alpha_{day} MS_{day} + \alpha_{run} MS_{run} + \alpha_{error} MS_{error})^2 / (\alpha_{day} MS_{day}^2) + (\alpha_{run} MS_{run}^2) + (\alpha_{error} MS_{error}^2) / DF_{error} \]

The CIs of repeatability were then computed using: 

\[ S_{R} = \left[ S_{R} \sqrt{df_{R} / \chi^{2}(1 - \alpha/2)^2} \right] \]

and \( S_{WL} = \left[ S_{WL} \sqrt{df_{WL} / \chi^{2}(1 - \alpha/2)^2} \right] \).

Table 1 Robustness test as described by Broeders et al. (2014)

| Combination No | Factor value | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|----------------|--------------|---|---|---|---|---|---|---|---|
| A or a         | A            | A | A | A | a | a | a | A | a |
| B or b         | B            | B | b | b | B | B | B | b | b |
| C or c         | C            | C | C | C | C | C | C | C | C |
| D or d         | D            | D | d | d | d | d | d | D | D |
| E or e         | E            | e | E | E | E | E | E | E | E |
| F or f         | F            | f | f | F | f | f | F | f | F |
| G or g         | G            | g | g | G | g | G | g | G | g |

(A) Standardised master mix; (a) alternative master mix; (B) standardised concentration of primers; (b) lower concentrations of primers; (C) standardised concentration of probe; (c) lower concentration of probe; (D) standardised alignment temperature; (d) upper alignment temperature; (E) standardised alignment temperature; (f) equipment used for validation; (f) alternative equipment; (G) operator 1; (g) operator 2
Quality assurance of the results
Parallel to the clinical samples, commercial exogenous internal controls were run to rule out errors in the DNA purification process: A TaqManRNase P Detection Reagent Kit (Applied Biosystems, CA, USA) was applied following manufacturer instructions. The thermal profile conditions were the same as those used for amplification of the sip gene.

Statistical analysis
The GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA) was used to carry out ANOVA analysis to determine the precision of the method and normal data distribution tests for choose the equation that determined the LOB and LOD, according to guidelines provided by CLSI documents EP05A3 and EP17-A, respectively.

Results
Determining the analytical parameters of the qPCR assay of GBS
Analytical validation of the qPCR assay was obtained using the parameters specified. The first to be determined was necessarily the anticipated reportable range. The high and low concentrations were measured in GEs per microliter. The anticipated reportable range, determined by constructing two standard curves, showed a linear correlation between the expected and obtained values ($R^2 = 0.9937$) and between the assigned values for $Ct$ and those found by the analytical software ($R^2 = 0.9997$) when the analyte was between 20E04 and 2 GE/μL (Fig. 2). The sixth point on the curve (0.2 GE/μL) was not amplified in any of the 24 replicates run during the four tests designed to determine this parameter. The $Ct$ values at the lowest detectable dilution (2 GE/μL) ranged from 33.06 to 35.36. The LOD (0.7 GE/μL) correlated with the results of the anticipated reportable range.

Table 2 Summary of results for each parameter evaluated in the analytical validation

| Validation parameters                        | sip-qPCR | GBS ATCC 12403 serotype III |
|----------------------------------------------|----------|----------------------------|
| **Inclusivity (detectable for qPCR) (fg/μL)**|          |                           |
| GBS serotype Ia (n = 3)                      | 24       |                           |
| GBS serotype Ib (n = 2)                      | 24       |                           |
| GBS serotype II (n = 4)                      | 24       |                           |
| GBS serotype III (n = 2)                     | 24       |                           |
| GBS serotype IV (n = 3)                      | 24       |                           |
| GBS serotype V (n = 2)                       | 24       |                           |
| GBS serotype VI (n = 2)                      | 24       |                           |
| GBS serotype VII (n = 3)                     | 24       |                           |
| GBS serotype VIII (n = 1)                    | 24       |                           |
| **Exclusivity (non-detectable qPCR) (0.1 to 1000 pg/μL)** | |                           |
| S. pyogenes ATCC 12384                        | ND       |                           |
| S. aureus ATCC 25923                         | ND       |                           |
| E. faecalis ATCC 29212                       | ND       |                           |
| S. pneumoniae ATCC 49619                     | ND       |                           |
| E. coli ATCC 25922                           | ND       |                           |
| K. pneumoniae ATCC 700603                    | ND       |                           |
| K. aerogenes ATCC 13048                      | ND       |                           |
| S. saprophyticus                             | ND       |                           |
| Proteus spp                                  | ND       |                           |
| S. marcescens                                | ND       |                           |
| **Reportable range (GE/μL)**                 |          |                           |
| GBS ATCC 12403 serotype III                  | 20.000-2 |                           |
| **Limit of detection (GE/μL)**               |          |                           |
| GBS ATCC 12403 serotype III                  | 0.7      |                           |
| **Robustness**                               |          |                           |
| GBS ATCC 12403 serotype III (% correct positives) | 100     |                           |
| Samples non-GBS (% correct negatives)        | 100      |                           |
| **PCR efficiency (ε) (%)**                   |          |                           |
|                                             | 105.4    |                           |
| **Linearity ($R^2$)**                        |          |                           |
|                                             | 0.9937   |                           |

Fig. 2 Determination of the anticipated reportable range. a Standard curve between the value assignment (log₁₀ GE/μL) and cycle threshold, as obtained from the points used to calculate real-time polymerase chain reaction efficiency (ε). b Linear regression of the points on the standard curve between the assigned values and those obtained from measurements (log₁₀ GE/μL). Also shown is the equation obtained from the model.
range, which lacked a detection signal when dilution was between 2 and 0.2 GE/μL.

Exclusivity tests demonstrated that qPCR did not detect DNA in the range of 1 to 1000 pg/μL for S. pyogenes ATCC 21547, S. aureus ATCC 25923, E. faecalis ATCC 29212, S. pneumoniae ATCC 49619, E. coli ATCC 25922, K. pneumoniae ATCC 700603, K. aerogenes ATCC 13048, S. saprophyticus, Proteus spp. or S. marcescens. The 21 strains that corresponded to 9 of 10 available serotypes (Ia, Ib and II to VIII) and the γ-hemolytic strain S. agalactiae ATCC 13813 (serotype II) were detected at low DNA concentrations (24 fg/μL or 10 GE/μL), revealing that qPCR is inclusive and able to independently detect the various strains of the serotype. Each parameter was found to have an analytical specificity of 100% (Table 2; Fig. 3). Robustness was shown: Every combination produced an amplification signal, and Ct values remained between 32 and 34.

**Discussion**

A qPCR method to directly identify GBS from vaginal-rectal swabs after an enrichment process in Todd-Hewitt broth was successfully developed. This methodology provides results that are the same as those obtained using the microbiological method routinely used in clinical laboratories. The qPCR methodology is quick and easy to interpret by technical health personnel, and it can be incorporated into a working algorithm to identify GBS. Analytical validation was performed by extracting gDNA using proteinase K, lysozymes and Chelex.

---

**Table 3** Confirmatory analysis of 103 clinical samples obtained from pregnant women

| Result        | qPCR | Microbiological Method | Total of samples analyzed |
|---------------|------|------------------------|---------------------------|
| Positive      | 15   | 15                     | 103                       |
| Negative      | 88   | 88                     |                           |
100, reducing costs compared to a genomic DNA purification kit. This methodology is advantageous compared to others because it can detect low concentrations of genomic DNA (2 GE/μL) and can potentially be used as a GBS screening tool at delivery directly from a vaginal swab. A disadvantage is that the CDC does not recommend this practice. Moreover, molecular methods are limited in GBS detection because antibiotic resistance genes have not yet been incorporated into the PCR primer set. Doing so could enable the development of a rapid test that will provide additional information such as antibiotic susceptibility, for example, in the context of a penicillin allergy [29]. Meanwhile, microbiological analyses are recommended for determining susceptibility.

Several molecular diagnostic tools are emerging as potential candidates for more rapid identification of invasive GBS disease or to rapidly identify women colonised with GBS [29]. Rapid diagnostic tests for invasive diseases include the MinIon®, loop-mediated isothermal amplification [17] and optical immunoassays. Those for rapid intrapartum colonisation screening include PCR-based methods [30]. However, publicly available data for the analytical validation of these methods for GBS screening in a clinical setting are lacking. Our analytical validation method assessed the performance of qualitative qPCR strategies based on the TaqMan probe for GBS detection, and it was conducted according to international guidelines. The sip gene from GBS was used as a molecular target, and inclusivity and exclusivity were estimated using gDNA from stocks of various bacterial strains. The analytical value of this methodology is in its anticipated reportable range (20,000 to 2 GE/μL) and its LOD (0.7 GE/μL). Additionally, it has a high level of precision in repeatability conditions, reinforcing its applicability (Supplementary Fig. 3, Supplementary Table 1 and Supplementary Table 2). During pregnancy, rectovaginal colonisation of GBS is not persistent; it is characterised by a high rate of new acquisitions and a loss of colonisation over the course of pregnancy [31]. A culture-based method applied to samples taken between the 35th and 37th weeks of gestation might fail to detect all colonisations at delivery because GBS could infect between sampling and the onset of labor. For this reason, an intrapartum screening strategy using a qPCR method to identify and quantify GBS would help avoid risk-factor-based screening [32]. Compared to GBS cultures in enriched media, PCR has better sensitivity and specificity, ranging from 62.5–100% and 84.6–100%, respectively [31].

To date, the gold standard for detecting GBS is the microbiological method, which is inexpensive and easy to perform. However, it fails to detect non-hemolytic
GBS strains, and β-hemolysis could be difficult to observe [7]. Therefore, negative samples should be further tested for other GBS strains using either a subculture on Granada agar plates, direct latex agglutination testing or (increasingly) molecular methods such as qPCR. Several clinical studies have been described for GBS detection by qPCR targeting the sip gene and have reported sensitivity between 95.4–97% and specificity between 84.6–99% (Supplementary Table 3); high sensitivity and specificity previously describes may be explained by the fact that the sip gene is conserved among all serotypes. On the other hand, none have declared analytical validation of the qPCR methodology, which could considerably improve future clinical validation studies. Although positive and negative controls are important when validating a result, a greater understanding of the methodology used, gained through analytical validation, is imperative. Our analytical validation parameters describe a trend that is similar to those seen with pathogens such as Trypanosoma cruzi (LOD, 0.23 and 0.70 parasite equivalents/mL) [13], Plasmodium knowlesi (analytical sensitivity, 10 copies/μL) [33] and the American H7 virus (10E3 and 10E4 gene copies per reaction) [34]. Finally, the availability of this standardised and validated qPCR method provides new possibilities for screening women in labor and helps to improve the detection of GBS strains using microbiological methods.

Using qPCR to detect the sip gene has been reported elsewhere, and sensitivity and specificity were acceptable [16, 19, 20, 35, 36] (Supplementary Table 3). However, we established the limitations of this amplification process using analytical validation. Furthermore, our methodology, when compared with traditional methods currently considered to be the gold standard for GBS detection, shows 100% correlation. Nevertheless, the potential of this test should be explored because it could reduce swab incubation time or possibly allow direct extraction of genetic material. The technique developed here allows GBS to be detected in polymicrobial samples, and its specificity is superior compared to the microbiological method, which requires 3 to 5 days for incubation.

**Conclusion**

This kit accurately detects the bacterial agent GBS, it avoids cross-reactions with related bacteria and it provides 100% analytical specificity. It has a low LOD (0.7 GE/μL or 14 genomes per reaction) and optimal performance, and it meets analytical needs, as shown in its linearity and efficiency data, which correlates with current screening methods. These preliminary results are favorable and provide the basis for a study with a greater sample size, which could confirm the effectiveness of this test using clinical validation.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12884-020-03038-z.

**Additional file 1: Table S1.** The analysis of variance summary for data collected from three concentrations used to estimate the precision parameter. Note: DF: degrees of freedom; MS: mean of the squares; SS: sum of the squares.

**Additional file 2: Table S2.** Summary of the data from three concentrations used for estimating confidence intervals for repeatability and inter-laboratory precision. Abbreviation: CI: 95% Confidence interval. Repeatability results: at 2 GE/μL, 95.5% CV [CI, 7.8–12.2]; at 4 GE/μL, 5.9% CV [CI, 4.9–7.6]; and at 100 GE/μL, 1.8% CV [CI, 1.5–2.4]. Intra-laboratory precision results: at 2 GE/μL, 12% CV [CI, 9.9–14.1]; at 4 GE/μL, 8.8% CV [CI, 6.6–9.3]; and at 100 GE/μL, 2.9% CV [CI, 1.9–2.7].

**Additional file 3: Table S3.** Results of various studies of qPCR analysis using the sip gene as the target for GBS detection.

**Additional file 4: Figure S1.** Alignment of the sip gene and oligonucleotides (118 bp).

**Additional file 5: Figure S2.** Detection of the Streptococcus agalactiae sip gene using qPCR. A Typical amplification plot using 2300 GE/μL as the DNA template. dRn, fluorescent signal using ROX as a passive reference. B The polymerase chain reaction (PCR) product from A was fractionated on a 2% agarose gel and visualised using gel red staining. Lane 1, DNA molecular weight marker, through analytical validation bp; lanes 2 and 3, PCR product, 2300 GE/μL; lanes 4 and 5, no-template control.

**Additional file 6: Figure S3.** Daily runs used to estimate within-laboratory precision. Three bacterial concentrations from ATCC 12403 (2, 4 and 100 GE/μL), represented as log10 GE/mL, were evaluated using a single-site design of 20x2x2 according to the CLSI EP05-A3 guidelines. A Values (log10 GE/mL) for the 2 GE/μL concentration obtained from four daily replications over twenty days. B Values (log10 GE/mL) for the 4 GE/μL concentration obtained from four daily replications over twenty days. C Values (log10 GE/mL) for the 100 GE/μL concentration obtained from four daily replications over twenty days.

**Abbreviations**

ATCC: American Type Culture Collection; bp: base pair; CAMP: Christie, Atkins and Munch-Peterson; CDC: Centers for Disease Control and Prevention; CLSI: Clinical and Laboratory Standards Institute; Ct: Cycle threshold; DNA: Deoxyribonucleic acid; GBS: Group B Streptococcus; LOD: Limit of detection; LOB: Limit of blank; Mbp: Megabase pair; PCR: Polymerase chain reaction; qPCR: Real-time PCR; SIP: Surface immunogenic protein

**Acknowledgments**

The authors thank all members of the Bacteriology Laboratory of the Health Public Institute of Chile, in particular, Pamela Araya, Bianca Rojas, Soledad Castro, Ingrid Araya, María Soledad Prat, Joselin Hormazábal, Jennifer Díaz, Clara Orellana and Rocío Agúero.

**Authors’ contributions**

SEI, DAS and AEV collected clinical samples; DFE, DD-D, CFH, DAS, RAM, CHP, DNB, CNO-B, PIA, RR and AEV performed analyses and interpreted the data; DFE, AMK and AEV conceived and designed the study; and DFE, DD-D and AEV made critical revisions to the manuscript. All authors have read and approve the final manuscript.

**Funding**

This study was supported by FONDEF D10i1202 (DAS, SEI and AEV) through the collection of clinical samples; by the Institute of Public Health in Santiago, Chile (DFE, DD-D, CFH, DAS, RAM, CHP, DNB, CNO-B and, RR AEV) through the performance of analyses and interpretation of data; and the Millennium Institute of Immunology and Immunotherapy, No. P09/016-F (DDD, CFH, DNB and AMK).
References

1. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012;379(9823):39–45.

2. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(S2):S160–S169.

3. Madrid L, Seale AC, Kohli-Lynch M, et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(5):S150–S160.

4. Russell NJ, Seale AC, O’Driscoll M, et al. Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(5):S160–S169.

5. Lin FC, Weisman LE, Azimi P, et al. Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B streptococcal disease. Pediatr Infect Dis J. 2011;30(9):759–763.

6. Patras KA, Nizet V. Group B streptococcal maternal colonization and neonatal disease: molecular mechanisms and preventative approaches. Front Pediatr. 2015;3:187.

7. Rosa-Fraile M, Spellberg B. Reliable detection of group B Streptococcus in the clinical laboratory. J Clin Microbiol. 2017;55(2):259–260.

8. Yancey MK, Schuchat A, Brown LK, et al. The accuracy of late antenatal screening cultures in predicting genital group B streptococcal colonization at delivery. Obstet Gynecol. 1996;88(1):5–11.

9. Davies JD, Miller MA, Faro S, et al. Multicenter study of a rapid 296 molecular-based assay for the diagnosis of group B Streptococcus colonization in pregnant women. Clin Infect Dis. 2004;39(11):129–135.

10. Miller SA, Deak E, Humphries R. Comparison of the AmpliVue, BD max system, and illumigene molecular assays for detection of group B Streptococcus in antenatal screening specimens. J Clin Microbiol. 2015;53:1938–1941.

11. Nishihara Y, Dangor Z, French N, et al. Challenges in reducing Group B Streptococcus disease in African settings. Arch Dis Child. 2017;102(7):72–73.

12. Six A, Firon A, Plainvert C, et al. Molecular characterization of nonhemolytic and nonpigmented group B streptococci responsible for human invasive infections. J Clin Microbiol. 2016;54:75–82.

13. Ramírez JC, Cura CJ, da Cruz MO, et al. Analytical validation of quantitative real-time PCR 308 methods for quantification of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. J Mol Diagn. 2015;17(5):605–615.

14. Brodeur BR, Beyer M, Charlebois I, et al. Identification of group B streptococcal sip protein, which elicits cross-protective immunity. Infect Immun. 2000;68(5):1010–1018.

15. Rioux S, Martin D, Ackermann H, et al. Localization of surface immunogenic protein on group B streptococcus. Infect Immun. 2001;69(5):1625–1632.

16. Bergseng H, Bevanger L, Rygg M, et al. Real-time PCR targeting the sip gene for detection of group B Streptococcus colonization in pregnant women at delivery. J Med Microbiol. 2007;56:223–8.

17. McKenna JP, Cox C, Fairley DJ, et al. Loop-mediated isothermal amplification assay for rapid detection of Streptococcus agalactiae (group B Streptococcus) in vaginal swabs—a proof of concept study. J Med Microbiol. 2017;66(1):294–300.

18. Feuerschette OM, Seratine AC, Bazzo ML, et al. Performance of RT-PCR in the detection of Streptococcus agalactiae in the anogenital tract of pregnant women. Arch Gynecol Obstet. 2012;286(4):347–42.

19. Contreras-Avila JA, Gutierrez-Fernandez J, Gonzalez-Espin A, et al. Comparison of qPCR and culture methods for Group B streptococcal colonization detection in pregnant women: evaluation of a new qPCR assay. BMC Infect Dis. 2018;18:305.

20. Khattar A, Randis TM, Chambry A, et al. Improving the sensitivity of real-time PCR detection of Group B Streptococcus using consensus sequence-derived oligonucleotides. Open Forum Infect Dis. 2018;5(suppl_1):S64.

21. National Committee for Clinical Laboratory Standards (NCCLS). Protocols for Determination of Limits of Detection and Limits of Quantitation; approved guideline. Wayne: NCCLS EP17-A, 2004.

22. Clinical and Laboratory Standards Institute (CLSI). Evaluation of Precision of Quantitative Measurement Procedures; approved guideline—third edition. Wayne: CLSI EP05-A3, 2014.

23. Clinical and Laboratory Standards Institute (CLSI). Verification and validation of multiplex nucleic acid assays; approved guideline. Wayne: CLSI MM17-A, 2008.

24. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(5):611–22.

25. Morozumi M, Chiba N, Igarashi Y, et al. Direct identification of Streptococcus agalactiae and capsular type by real-time PCR in vaginal swabs from pregnant women. J Infect Chemother. 2015;21:348–54.

26. Raymackers M, Smets R, Maes B, et al. Checklist for optimization and validation of real-time PCR assays. J Clin Lab Anal. 2009;23(1):45–51.

27. León CM, Muñoz M, Hernández C, et al. Analytical performance of four polymerase chain reaction (PCR) and real time PCR (qPCR) assays for the detection of six Leishmania species DNA in Colombia. Front Microbiol. 2017;8:1907.

28. Breeding KM, Raggiani B, Lee KJU, et al. Real-time PCR-based serotyping of Streptococcus agalactiae. Sci Rep. 2016;6:38523.

29. Le Doare KL, Heath PT, Plumb J, et al. Uncertainties in screening and prevention of group B Streptococcus disease. Aust N Z J Obstet Gynaecol. 2013;53:236–42.

30. De Rango GB, Melin P, Berardi A, et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Matern Fetal Neonatal Med. 2015;28:766–82.

31. Kwatra G, Adrian PV, Shirvili T, et al. Serotype-specific acquisition and loss of group B streptococcal sip protein, which elicits cross-protective immunity. Infect Immun. 2012;80(1):967–78.

32. Oliver PC, Skokoples SE, Singh B, et al. TaqMan real-time PCR assay for the detection and quantitation of Plasmodium knowlesi. Malari J. 2012;10:344.

33. Spackman E, Ip HS, Suarez DL, et al. Analytical validation of a real-time reverse transcription polymerase chain reaction test for pan-American
lineage H7 subtype avian influenza viruses. J Vet Diagn Invest. 2008;20:
612–6.
35. Bergh K, Stoelhaug A, Loeseth K, Bevanger L. Detection of group B streptococci (GBS) in vaginal swabs using real-time PCR with TaqMan probe hybridization. Indian J Med Res. 2004;119(Suppl):221–3.
36. El Aila NA, Tency I, Claeyts G, et al. Comparison of culture with two different qPCR assays for detection of rectovaginal carriage of Streptococcus agalactiae (group B streptococci) in pregnant women. Res Microbiol. 2011;162:499–505.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.